CHARLOTTE, N.C.–(BUSINESS WIRE)–cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one of the leading, and most highly trusted and recognized cannabidiol (CBD) brands, announced today that it has hired Dr. Sibyl Swift, as Vice President for Scientific & Regulatory Affairs. The Company previously announced in February 2020 that Dr. Swift had been engaged as a regulatory consultant to oversee the Company’s regulatory initiatives. She was also recently named as co-Chair of cbdMD Therapeutics, along with the company’s General Counsel, Lance Blundell. Prior to joining cbdMD, Dr. Swift was the Senior VP for Scientific & Regulatory Affairs at the Natural Products Association (NPA) where she led the association’s work in Codex, the Supplement Safety & Compliance Initiative (SSCI), and FDA policy. Prior to her time at the NPA, Dr. Swift was the associate director for research and strategy at the US Food and Drug Administration (FDA), where she directed the Office of Dietary Supplement Programs research agenda and worked closely on office policy and enforcement.

Dr. Swift will oversee the Company’s GMP compliance, internal product quality and safety initiatives, and direct the Company’s scientific work performed in support of world-wide regulatory submissions and claims substantiation. These efforts, and her outside work with standards setting organizations, such as AOAC’s CASP group demonstrates the Company’s continued commitment to providing its consumers with products that meet the highest regulatory standards for quality and safety.

“We have had the good fortune to be able to work with Dr. Swift over the past several months as she has guided cbdMD in its Novel Food Applications (“Applications”) with the United Kingdom’s Food Standards Agency (“FSA”) and the European Food Safety Authority (“EFSA”). Specifically, Dr. Swift helped with the Applications’ detailed analysis of the quality and stability of our products, our hemp sourcing and extraction controls, our labelling and testing requirements, and the underlying intake and toxicological data related to the safe consumption of the proprietary cannabinoid blend ingredients in our cbdMD product line. We are excited that Dr. Swift has joined our team at cbdMD in a full time capacity,” said Martin Sumichrast, Chairman & Co-CEO of cbdMD, Inc.

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products. Our cbdMD brand currently includes over 130 SKUs of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes. Our Paw CBD brand of pet products includes over 45 SKUs of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our CBD Botanicals brand of beauty and skincare products features 15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. Please visit www.cbdMD.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products. To learn more about cbdMD and their comprehensive line of U.S. grown, THC-free1 CBD oil products, please visit www.cbdmd.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 as filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2020 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

1 THC-free is defined as below the level of detection using validated scientific analytical tools.

Contacts

PR: 5W Public Relations

cbdMD@5wpr.com
(212) 999-5585

Investors: cbdMD, Inc.,

John Weston, Director of Investor Relations

John.Weston@cbdMD.com
(704) 249-9515

Contact Us

We're here to help! Just send us an email and we'll get back to you ASAP :)

Sending

©2021 CBD Social Network

or

Log in with your credentials

or    

Forgot your details?

or

Create Account